Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2010, Article ID 257835, 4 pages
http://dx.doi.org/10.1155/2010/257835
Clinical Study

PPAR 𝛾 Ligand as a Promising Candidate for Colorectal Cancer Chemoprevention: A Pilot Study

1Gastroenterology Division, Graduate School of Medicine, Yokohama City University, 3-9 Fuku-ura, Kanazawa-ku, Yokohama, 236-0004, Japan
2Gastroenterology and Hepatology Division, University of Rochester, Rochester, NY 14627, USA
3Biochemistry Division, National Cancer Center Research Institute, Chuo-Ku, Tokyo 104-0045, Japan

Received 30 April 2010; Revised 22 June 2010; Accepted 29 June 2010

Academic Editor: Dipak Panigrahy

Copyright © 2010 Hirokazu Takahashi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Takashima, Y. Fujiwara, K. Higuchi et al., “PPAR-gamma ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarboxylase activity,” International Journal of Oncology, vol. 19, no. 3, pp. 465–471, 2001. View at Google Scholar · View at Scopus
  2. T.-H. Chang and E. Szabo, “Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor γ in non-small cell lung cancer,” Cancer Research, vol. 60, no. 4, pp. 1129–1138, 2000. View at Google Scholar · View at Scopus
  3. R. N. DuBois, R. Gupta, J. Brockman, B. S. Reddy, S. L. Krakow, and M. A. Lazar, “The nuclear eicosanoid receptor, PPARγ, is aberrantly expressed in colonic cancers,” Carcinogenesis, vol. 19, no. 1, pp. 49–53, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. E. Mueller, P. Sarraf, P. Tontonoz et al., “Terminal differentiation of human breast cancer through PPARγ,” Molecular Cell, vol. 1, no. 3, pp. 465–470, 1998. View at Google Scholar · View at Scopus
  5. H. Sato, S. Ishihara, K. Kawashima et al., “Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists,” British Journal of Cancer, vol. 83, no. 10, pp. 1394–1400, 2000. View at Google Scholar · View at Scopus
  6. P. Tontonoz, S. Singer, B. M. Forman et al., “Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 1, pp. 237–241, 1997. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Takahashi, T. Okumura, W. Motomura, Y. Fujimoto, I. Kawabata, and Y. Kohgo, “Activation of PPARγ inhibits cell growth and induces apoptosis in human gastric cancer cells,” FEBS Letters, vol. 455, no. 1-2, pp. 135–139, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Niho, M. Takahashi, Y. Shoji et al., “Dose-dependent suppression of hyperlipidemia and intestinal polyp formation in Min mice by pioglitazone, a PPARγ ligand,” Cancer Science, vol. 94, no. 11, pp. 960–964, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Shimada, K. Kojima, K. Yoshiura, H. Hiraishi, and A. Terano, “Characteristics of the peroxisome proliferator activated receptor γ (PPARγ) ligand induced apoptosis in colon cancer cells,” Gut, vol. 50, no. 5, pp. 658–664, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Shen, C. Deng, and M. Zhang, “Peroxisome proliferator-activated receptor γ agonists inhibit the proliferation and invasion of human colon cancer cells,” Postgraduate Medical Journal, vol. 83, no. 980, pp. 414–419, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. M. A. Karim Rumi, H. Sato, S. Ishihara, C. Ortega, Y. Kadowaki, and Y. Kinoshita, “Growth inhibition of esophageal squamous carcinoma cells by peroxisome proliferator-activated receptor-γ ligands,” Journal of Laboratory and Clinical Medicine, vol. 140, no. 1, pp. 17–26, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Eibl, M. N. Wente, H. A. Reber, and O. J. Hines, “Peroxisome proliferator-activated receptor γ induces pancreatic cancer cell apoptosis,” Biochemical and Biophysical Research Communications, vol. 287, no. 2, pp. 522–529, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Ohta, T. Endo, K. Haraguchi, J. M. Hershman, and T. Onaya, “Ligands for peroxisome proliferator-activated receptor γ inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 5, pp. 2170–2177, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. K. L. Schaefer, “PPARγ inhibitors as novel tubulin-targeting agents,” PPAR Research, vol. 2008, Article ID 785405, 9 pages, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. Y.-F. Guan, Y.-H. Zhang, R. M. Breyer, L. Davis, and M. D. Breyer, “Expression of peroxisome proliferator-activated receptor γ (PPARγ) in human transitional Bladder cancer and its role in inducing cell death,” Neoplasia, vol. 1, no. 4, pp. 330–339, 1999. View at Google Scholar · View at Scopus
  16. S. Kitamura, Y. Miyazaki, Y. Shinomura, S. Kondo, S. Kanayama, and Y. Matsuzawa, “Peroxisome proliferator-activated receptor γ induces growth arrest and differentiation markers of human colon cancer cells,” Japanese Journal of Cancer Research, vol. 90, no. 1, pp. 75–80, 1999. View at Google Scholar · View at Scopus
  17. W. Su, B. M. Necela, K. Fujiwara et al., “The high affinity peroxisome proliferator-activated receptor-gamma agonist RS5444 inhibits both initiation and progression of colon tumors in azoxymethane-treated mice,” International Journal of Cancer, vol. 123, no. 5, pp. 991–997, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Fujisawa, A. Nakajima, N. Fujisawa et al., “Peroxisome proliferator-activated receptor γ (PPARγ) suppresses colonic epithelial cell turnover and colon carcinogenesis through inhibition of the β-catenin/T cell factor (TCF) pathway,” Journal of Pharmacological Sciences, vol. 106, no. 4, pp. 627–638, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. E. Osawa, A. Nakajima, K. Wada et al., “Peroxisome proliferator-activated receptor γ ligands suppress colon carcinogenesis induced by azoxymethane in mice,” Gastroenterology, vol. 124, no. 2, pp. 361–367, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. C. A. McAlpine, Y. Barak, I. Matise, and R. T. Cormier, “Intestinal-specific PPARγ deficiency enhances tumorigenesis in ApcMin/+ mice,” International Journal of Cancer, vol. 119, no. 10, pp. 2339–2346, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. W. F. Anderson, A. Umar, and O. W. Brawley, “Colorectal carcinoma in black and white race,” Cancer and Metastasis Reviews, vol. 22, no. 1, pp. 67–82, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Rougier and E. Mitry, “Epidemiology, treatment and chemoprevention in colorectal cancer,” Annals of Oncology, vol. 14, no. 2, pp. ii3–ii5, 2003. View at Google Scholar · View at Scopus
  23. G. Debrock, V. Vanhentenrijk, R. Sciot, M. Debiec-Rychter, R. Oyen, and A. Van Oosterom, “A phase II trial with rosiglitazone in liposarcoma patients,” British Journal of Cancer, vol. 89, no. 8, pp. 1409–1412, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. M. H. Kulke, G. D. Demetri, N. E. Sharpless et al., “A phase II study of troglitazone, an activator of the PPARγ receptor, in patients with chemotherapy-resistant metastatic colorectal cancer,” Cancer Journal, vol. 8, no. 5, pp. 395–399, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. R. P. Bird, “Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings,” Cancer Letters, vol. 37, no. 2, pp. 147–151, 1987. View at Google Scholar · View at Scopus
  26. T. P. Pretlow, M. A. O'Riordan, G. A. Somich, S. B. Amini, and T. G. Pretlow, “Aberrant crypts correlate with tumor incidence in F344 rats treated with azoxymethane and phytate,” Carcinogenesis, vol. 13, no. 9, pp. 1509–1512, 1992. View at Google Scholar · View at Scopus
  27. T. Takayama, S. Katsuki, Y. Takahashi et al., “Aberrant crypt foci of the colon as precursors of adenoma and cancer,” New England Journal of Medicine, vol. 339, no. 18, pp. 1277–1284, 1998. View at Publisher · View at Google Scholar · View at Scopus
  28. E. T. Jacobs, A. R. Giuliano, D. J. Roe et al., “Intake of supplemental and total fiber and risk of colorectal adenoma recurrence in the wheat bran fiber trial,” Cancer Epidemiology Biomarkers and Prevention, vol. 11, no. 9, pp. 906–914, 2002. View at Google Scholar · View at Scopus
  29. M. L. McCullough, R. M. Bostick, C. R. Daniel et al., “Vitamin D status and impact of vitamin D3 and/or calcium supplementation in a randomized pilot study in the Southeastern United States,” Journal of the American College of Nutrition, vol. 28, pp. 678–686, 2009. View at Google Scholar
  30. B. F. Cole, R. F. Logan, S. Halabi et al., “Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials,” Journal of the National Cancer Institute, vol. 101, no. 4, pp. 256–266, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. J. A. Zell, A. Ziogas, L. Bernstein et al., “Nonsteroidal anti-inflammatory drugs: effects on mortality after colorectal cancer diagnosis,” Cancer, vol. 115, no. 24, pp. 5662–5671, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. Vinogradova, J. Hippisley-Cox, C. Coupland, and R. F. Logan, “Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study,” Gastroenterology, vol. 133, no. 2, pp. 393–402, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. R. S. Bresalier, R. S. Sandler, H. Quan et al., “Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial,” New England Journal of Medicine, vol. 352, no. 11, pp. 1092–1102, 2005. View at Publisher · View at Google Scholar · View at Scopus